TY - JOUR
T1 - Pulmonary hypertension in heart failure with preserved ejection fraction
T2 - A plea for proper phenotyping and further research
AU - Hoeper, Marius M.
AU - Lam, Carolyn S.P.
AU - Vachiery, Jean Luc
AU - Bauersachs, Johann
AU - Gerges, Christian
AU - Lang, Irene M.
AU - Bonderman, Diana
AU - Olsson, Karen M.
AU - Gibbs, J. Simon R.
AU - Dorfmuller, Peter
AU - Guazzi, Marco
AU - Galie, Nazzareno
AU - Manes, Alessandra
AU - Handoko, M. Louis
AU - Vonk-Noordegraaf, Anton
AU - Lankeit, Mareike
AU - Konstantinides, Stavros
AU - Wachter, Rolf
AU - Opitz, Christian
AU - Rosenkranz, Stephan
PY - 2017/10/7
Y1 - 2017/10/7
N2 - Heart failure (HF) with preserved ejection fraction (HFpEF) is a common disease affecting the elderly in particular. Up to 80% of these patients develop pulmonary hypertension (PH), which is associated with worse symptoms and increased mortality.1 It is a matter of concern that drugs approved for pulmonary arterial hypertension (PAH) are sometimes used in such patients despite insufficient data for their safety and efficacy. On the other hand, the impact of PH and right ventricular (RV) dysfunction on morbidity and mortality in HFpEF call for proper attention both at the clinical and scientific level. Here we discuss the clinical problem, pathophysiology, diagnostic shortfalls, gaps in evidence, and future strategies for PH-HFpEF.
AB - Heart failure (HF) with preserved ejection fraction (HFpEF) is a common disease affecting the elderly in particular. Up to 80% of these patients develop pulmonary hypertension (PH), which is associated with worse symptoms and increased mortality.1 It is a matter of concern that drugs approved for pulmonary arterial hypertension (PAH) are sometimes used in such patients despite insufficient data for their safety and efficacy. On the other hand, the impact of PH and right ventricular (RV) dysfunction on morbidity and mortality in HFpEF call for proper attention both at the clinical and scientific level. Here we discuss the clinical problem, pathophysiology, diagnostic shortfalls, gaps in evidence, and future strategies for PH-HFpEF.
UR - http://www.scopus.com/inward/record.url?scp=85032159863&partnerID=8YFLogxK
U2 - https://doi.org/10.1093/eurheartj/ehw597
DO - https://doi.org/10.1093/eurheartj/ehw597
M3 - Review article
C2 - 28011705
SN - 0195-668X
VL - 38
SP - 2869
EP - 2873
JO - European Heart journal
JF - European Heart journal
IS - 38
ER -